Intervention

Octreotide Acetate

ClinicalTrials.gov intervention label

Clinical trials5
Recruiting0
Common conditions25
Lead sponsors shown3

Clinical trials

5 shown
Human Models of Selective Insulin Resistance: Pancreatic ClampNCT06558422 · 2027-01-01
NOT_YET_RECRUITING
Dexamethasone/Pancreatic Clamp P&FNCT06126354 · 2024-07-01
WITHDRAWN
Pancreatic Clamp in NAFLDNCT05724134 · 2023-08-29
COMPLETED
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsNCT03879694 · 2019-06-17
COMPLETED
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNCT01204476 · 2010-10-01
COMPLETED

Common conditions

Insulin Resistance3Non-Alcoholic Fatty Liver Disease3Prediabetic State3Hyperinsulinemia2Obesity2Gastrin-Producing Neuroendocrine Tumor1Lung Atypical Carcinoid Tumor1Lung Carcinoid Tumor1Lung Typical Carcinoid Tumor1Metabolic Dysfunction Associated Steatotic Liver Disease1Metastatic Digestive System Neuroendocrine Tumor G11Metastatic Pancreatic Neuroendocrine Tumor1Overweight and Obesity1Pancreatic Glucagonoma1Pancreatic Insulinoma1Pancreatic Polypeptide Tumor1Paraganglioma1Recurrent Digestive System Neuroendocrine Tumor G11Recurrent Merkel Cell Carcinoma1Recurrent Pancreatic Neuroendocrine Carcinoma1Regional Digestive System Neuroendocrine Tumor G11Somatostatin-Producing Neuroendocrine Tumor1Stage III Merkel Cell Carcinoma1Stage IV Merkel Cell Carcinoma1Thyroid Gland Medullary Carcinoma1

Trial status mix

COMPLETED3
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.